Drug Interactions between Sutent and tivozanib
This report displays the potential drug interactions for the following 2 drugs:
- Sutent (sunitinib)
- tivozanib
Interactions between your drugs
No interactions were found between Sutent and tivozanib. However, this does not necessarily mean no interactions exist. Always consult your healthcare provider.
Sutent
A total of 486 drugs are known to interact with Sutent.
- Sutent is in the following drug classes: multikinase inhibitors, VEGF/VEGFR inhibitors.
- Sutent is used to treat the following conditions:
tivozanib
A total of 62 drugs are known to interact with tivozanib.
- Tivozanib is in the drug class VEGF/VEGFR inhibitors.
- Tivozanib is used to treat Renal Cell Carcinoma.
Drug and food interactions
SUNItinib food
Applies to: Sutent (sunitinib)
GENERALLY AVOID: Consumption of grapefruit or grapefruit juice during sunitinib therapy may increase the plasma concentrations of sunitinib. The proposed mechanism is inhibition of CYP450 3A4-mediated metabolism by certain compounds present in grapefruit.
MANAGEMENT: Although clinical data are lacking, it may be advisable to avoid the consumption of large amounts of grapefruit or grapefruit juice during sunitinib therapy.
References (1)
- (2006) "Product Information. Sutent (sunitinib)." Pfizer U.S. Pharmaceuticals Group
Therapeutic duplication warnings
Therapeutic duplication is the use of more than one medicine from the same drug category or therapeutic class to treat the same condition. This can be intentional in cases where drugs with similar actions are used together for demonstrated therapeutic benefit. It can also be unintentional in cases where a patient has been treated by more than one doctor, or had prescriptions filled at more than one pharmacy, and can have potentially adverse consequences.
Vegf/vegfr inhibitors
Therapeutic duplication
The recommended maximum number of medicines in the 'VEGF/VEGFR inhibitors' category to be taken concurrently is usually one. Your list includes two medicines belonging to the 'VEGF/VEGFR inhibitors' category:
- Sutent (sunitinib)
- tivozanib
Note: In certain circumstances, the benefits of taking this combination of drugs may outweigh any risks. Always consult your healthcare provider before making changes to your medications or dosage.
See also
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.